Professor Chris Mason MBBS PhD FSB FRCSI FRCS

Cell Therapy + Regenerative Medicine Bioprocessing Unit
Advanced Centre for Biochemical Engineering
University College London


GMC Registration Number: 4121734

Professor Chris Mason is internationally recognized to be at the forefront of the emerging fields of cell therapy & regenerative medicine translation & commercialization. A background in basic science, clinical medicine, bioprocessing & business allows Chris a unique insight & understanding of the challenges facing the cell-based therapy sector as it grows into a competitive & sustainable global healthcare industry.

Chris holds a Clinical Sciences Degree from
Imperial College London, a Medical Degree from the United Medical & Dental Schools of Guy’s & St. Thomas’s Hospitals (now King’s College London) & a PhD under the supervision of Prof. Peter Dunnill in tissue-engineering bioprocessing from University College London.

Following graduation, Chris specialized in surgery & is a Fellow of the
Royal College of Surgeons both of England & in Ireland. Today, after a transition from clinical practice to translational research, he holds a Personal Chair in Regenerative Medicine Bioprocessing in the UCL Advanced Centre for Biochemical Engineering & is on the Steering Committee for the UCL Centre for Stem Cells & Regenerative Medicine. Other responsibilities include; being Senior Editor of "Regenerative Medicine" journal, Trustee of the UK Stem Cell Foundation (UKSCF) & the British Neurological Research Trust, co-founder & CEO of the London Regenerative Medicine Network (LRMN) - the world’s first & largest regenerative medicine network, member of the UK-Israel Life Sciences Council, member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group of the Commission on Human Medicines, & member of the United States Pharmacopeia (USP) Monographs - Biologics & Biotechnology Expert Committee.

Chris is on a number of national & international committees, working groups & initiatives related to the academic, clinical & commercial advancement of cell-based therapies & tissue engineering including; Chair of the
BIA Cell Therapy & Regenerative Medicine Industry Group, member of the Regenerative Medicine Expert Group (UK Government policy advisory group), member of the Canadian Network of Centres of Excellence (NCE) Standing Selection Committee, & member of the ISSCR Industry Committee, the Alliance for Regenerative Medicine (ARM) Communication & Education Committee & ISCT Commercialization Committee. He is on the Strategic Advisory Board of the Canadian Centre for the Commercialisation of Regenerative Medicine (CCRM) & Advisory Boards of a number of companies based in North America. On many occasions Chris has acted as a general spokesperson for the sector including newspaper, radio, TV & webinar interviews plus frequent news briefings. The Cell Therapy Industry Index (CTI), published biannually in Cell Stem Cell is produced by Chris & his collaborators at the Harvard Stem Cell Institute, LRMN & Proteus Regenerative Medicine.

Having won several
awards, Chris was particularly delighted to have had the opportunity in 2007 to give a Royal Institution of Great Britain, Friday Evening Discourse - "Therapeutic potential of human stem cells: promise & pitfalls" & again in 2013 - “The race to be a Cell Therapy Nation”. Chris also participated in the 2013 Vatican Stem Cell Conference & expressed his firmly held view that all cell types potentially have a role to play in therapy.

Chris lives on the beautiful
south coast of England & is happily married to Dr. Louise Mason. Louise is a Consultant Physician in Palliative Medicine at a leading UK teaching hospital & a Fellow of the Royal College of Physicians.